Founded in 1990, OR&L Commercial Real Estate provides complete real estate services including Selling and Leasing of Commercial Real Estate locally, nationally, and internationally. The company specializes in representing major industrial and office property owners, investors, tenant / buyer representation for corporations and not for profit organizations, new construction development, built to suit medical requirements and turn-key laboratory space development for Bio-Science companies.

Unique to O,R&L is the alliance between its four divisions – Brokerage, Construction, Property Management and Maintenance. These integrated business services work together to analyze their clients’ business needs, identify appropriate alternatives, examine the cost of retro-fit or new construction, and create an on-going budget to maximize efficiency while minimizing operating expenses. Each division is supervised by one of the four partners in his area of expertise. The partners have a successful background in advising investors, corporations, and public institutions on the complex issues affecting business owners and managers.

Curatix LLC focuses on the development of new antimicrobial therapies and therapeutic strategies with a specific focus on antifungal and anti-parasitic drugs and diagnostic tests.

Research Activities:

– Examine the antifungal activity of ELV compounds against various fungal pathogens in vitro and in mice

– Determine the in vitro and in vivo safety profiles of the lead compounds

– Continue optimization of the lead compounds

– Identify novel PAMS as potentiators of antifungal susceptibility.

Virtus Therapeutics (C-corp) is focused on the development of the first treatment for pantothenate kinase-associated neurodegeneration (PKAN) using small molecule activators.

Research Activities:

– Evaluate the activity of VTACs in cell-based assays

– Select advanced derivatives of VTACs using biochemical, structural and cell biological assays.

– Evaluate the activity of VTACs in animal models of PKAN

BioMed X is an independent research institute located in Germany and now in the US. We operate at the interface between academia and industry and perform biomedical research in the fields of oncology, immunology, neuroscience and platform technologies.

All of our research projects are sponsored by leading pharmaceutical companies and conducted by early career scientists recruited from the best schools around the world. The combination of global crowd sourcing with local incubation of the best research talents and ideas allows us to solve the biggest challenges in biomedical research.

We stand for free, creative, and curiosity-driven research combined with a solid validation of results, timelines, and deliverables. We serve a large purpose in advancing translational biomedicine by leveraging synergies and fostering cross-pollination across disciplines.

KnockMedia is a full-stack UX agency based in Yale Science Park, New Haven. Our focus on user interfaces and platforms that work for our clients and their end-users has led to several engagements with Artificial Intelligence and Data Science platforms who recognize the need for great interfaces to present and manipulate valuable data. We solve business, marketing and consumer engagement challenges with digital platforms, websites and applications for desktop, mobile and wearables.

Digital Health is an area of great interest to the KnockMedia team.

KnockMedia clients include Yale Ventures, Yale School of Architecture, TED Talks and Booking.com. Healthcare clients include Clifford Beers and Pacific AIDS Education and Training Center. Our clients work with us because they recognize the importance of a thoughtful approach to user experience and robust platforms when investing in digital solutions.

GSK is a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. We prioritize innovation in vaccines and specialty medicines to prevent and treat disease.

JBK Associates International, Inc. is an award-winning, executive talent solutions organization specializing in the acquisition, management, and development of senior-level talent across a wide spectrum of functional responsibilities and industries. Founded in 2003 by Julie Kampf, the vision for the company since its inception has been to create a full-service talent solutions firm with a distinct differentiation. As a “boutique”, JBK prides itself on its “high touch/high return” philosophy and values. Our client relationships are truly partnerships, where we strive to be a trusted advisor and extension of our client team, thereby understanding the intricacies and culture of each and every one of our clients. At JBK Associates, the successful execution of a search assignment is the collaborative effort of the entire JBK team- we believe in everyone taking ownership of the quality of an outcome when a client engages JBK Associates as their search partner, they are on the receiving end of a collective experience base of more than 50 years. The firm has an unparalleled commitment to diversity and inclusion across all touch points of an assignment which is substantiated by metrics and further evidenced by our own work environment. We understand that excellence comes from all perspectives, so we treat diversity as a necessity, not a nice to have.

Aspira Women’s Health Inc. is transforming gynecological health with the discovery, development, and commercialization of innovative testing options for women of all races and ethnicities, starting with ovarian cancer.    

Our ovarian cancer risk assessment portfolio is marketed to healthcare providers as OvaSuite^SM, which includes OvaWatch^SM, a non-invasive, blood-based test intended for use in the initial clinical assessment of ovarian cancer risk in women with benign or indeterminate adnexal masses for which surgical intervention may be either premature or unnecessary. With a negative predictive value (NPV) of 99%, OvaWatch allows physicians to confidently rule out ovarian cancer malignancy and choose the appropriate clinical management for the right patient at the right time. Ova1Plus^® combines our FDA-cleared products, Ova1^®and Overa^®, to detect risk of ovarian malignancy in women with adnexal masses planned for surgery.    

EndoCheck^SM, Aspira’s first-of-its-kind non-invasive diagnostic test for endometriosis, is currently in development. Visit our website for more information at www.aspirawh.com.   

Wyant Simboli is a corporate story/branding partner focused on working closely with biopharma founders and CEOs to help define their company story, structure the aligned brand, and inspire their audiences. For more than 30 years, we’ve succeeded in helping our clients grow by building robust and extensible brand communications systems designed to meet current and future opportunities.

Luna Bioscience, Inc. is an R&D company developing solutions to globally-important infectious diseases with enormous unmet needs, in the form of vaccines, diagnostics, and therapeutics for livestock, companion animals and humans. We have proof-of-principle in two animal models for a novel vaccine candidate against leptospirosis, and are working on solutions to additional infectious diseases. Our novel genomics-based technology comes out of the Vinetz lab at Yale.

Research Activity:

Finding and developing solutions to globally-important infectious diseases with enormous unmet needs.